Edwards Lifesciences (EW) CVP exercises options and sells 1,019 shares

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported an option exercise and related share sale. On 01/09/2026, he exercised an Employee Stock Option for 1,019 shares of common stock at an exercise price of $59.2567 per share and acquired the underlying shares. On the same day, he sold 1,019 shares of common stock at a weighted average price of $85.7037 per share, in multiple trades executed between $85.45 and $85.95.

After these transactions, Lippis directly beneficially owned 22,001.9103 shares of Edwards Lifesciences common stock and 4,076 Employee Stock Options (right to acquire). The filing states that these transactions were carried out under a Rule 10b5-1 trading plan adopted by the reporting person on July 30, 2025.

Insider Trade Summary

Net Seller: 1,019 shares ($87,332)

Net Sell 3 txns

Insider Lippis Daniel J.

Role CVP, TAVR

Sold 1,019 shs ($87K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire)	1,019	$0.00	--
Exercise	Common Stock	1,019	$59.2567	$60K
Sale	Common Stock	1,019	$85.7037	$87K

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 4,076 shares (Direct); Common Stock — 23,020.91 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. This transaction was executed in multiple trades at prices ranging from $85.45 to $85.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of theIssuer, full information regarding the number of shares and prices at which the transaction was effected.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TAVR

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		M(1)		1,019	A	$59.2567	23,020.9103	D
Common Stock	01/09/2026		S(1)		1,019	D	$85.7037(2)	22,001.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$59.2567	01/09/2026		M			1,019	05/08/2020	05/07/2026	Common Stock	1,019	$0.0000	4,076	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.

2. This transaction was executed in multiple trades at prices ranging from $85.45 to $85.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of theIssuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider reporting this Form 4 for Edwards Lifesciences (EW)?

The reporting person is Daniel J. Lippis, who serves as an officer of Edwards Lifesciences Corp with the title CVP, TAVR.

What transactions did Daniel J. Lippis report in Edwards Lifesciences (EW) stock?

On 01/09/2026, Lippis exercised an Employee Stock Option for 1,019 shares of common stock at an exercise price of $59.2567 per share and then sold 1,019 shares of common stock at a weighted average price of $85.7037 per share.

How many Edwards Lifesciences (EW) shares does Daniel J. Lippis own after the reported transactions?

Following the reported transactions, Lippis directly beneficially owned 22,001.9103 shares of Edwards Lifesciences common stock and 4,076 Employee Stock Options (right to acquire).

Were the Edwards Lifesciences (EW) insider transactions under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 30, 2025.

At what prices were the Edwards Lifesciences (EW) shares sold by Daniel J. Lippis?

The sale of 1,019 shares of common stock was executed in multiple trades at prices ranging from $85.45 to $85.95. The Form 4 reports a weighted average sale price of $85.7037 per share.

What type of derivative security did Daniel J. Lippis exercise related to Edwards Lifesciences (EW)?

He exercised an Employee Stock Option (Right to Acquire) with an exercise price of $59.2567 per share, covering 1,019 shares of Edwards Lifesciences common stock.